



IFW \$

**SUPPLEMENTAL
AMENDMENT
FEE TRANSMITTAL**

Attorney Docket No.	22338-00501/P1447R1/
Application Number	10/015,967
Filing Date	December 7, 2001
First Named Inventor	Dan L. Eaton.
Group Art Unit	1646
Examiner Name	Jiang, Dong

AMOUNT ENCLOSED 0.00

FEE CALCULATION (fees effective 12/08/03)

CLAIMS AS AMENDED	Claims Remaining After Amendment	Highest Number Previously Paid For	Number Extra	Rate	Calculations
TOTAL CLAIMS	9	- 20 =	0	X \$50.00 =	\$ 0.00
INDEPENDENT CLAIMS	4	- 3 =	1	X \$200.00 =	200.00

Since an Office Action set and extendable due date from _____, petition is hereby made for an extension to cover the date this reply is filed for which the requisite fee is enclosed (1 month (\$120)); (2 months (\$450)); (3 months (\$1,020)); (4 months (\$1,590)); (5 months (\$2,160)):

0.00

If Notice of Appeal is enclosed, add (\$500.00)

If Statutory Disclaimer under Rule 20(d) is enclosed, add fee (\$130.00)

Information Disclosure Statement (Rule 1.17(p)) (\$180.00)

\$ 180.00

Total of above Calculations =

\$ 380.00

Reduction by 50% for filing by small entity (37 CFR 1.9, 1.27 & 1.28)

TOTAL FEES DUE =

\$ 380.00

(1) If entry (1) is less than entry (2), entry (3) is "0".

(2) If entry (2) is less than 20, change entry (2) to "20".

(4) If entry (4) is less than entry (5), entry (6) is "0".

(5) If entry (5) is less than 3, change entry (5) to "3".

METHOD OF PAYMENT

- ☐ Check enclosed as payment.
- ☒ Charge "TOTAL FEES DUE" to the Deposit Account No. below.
- ☐ No payment is enclosed and no charges to the Deposit Account are authorized at this time (unless specifically required to obtain a filing date).

GENERAL AUTHORIZATION

- ☒ If the above-noted "AMOUNT ENCLOSED" is not correct, the Commissioner is hereby authorized to credit any overpayment or charge any additional fees necessary to:

Deposit Account No. 18-1260

Deposit Account Name Sidley Austin LLP

- ☒ The Commissioner is also authorized to credit any overpayments or charge any additional fees required under 37 CFR 1.16 (filing fees) or 37 CFR 1.17 (processing fees) during the prosecution of this application, including any related application(s) claiming benefit hereof pursuant to 35 USC § 120 (e.g., continuations/divisionals/CIPs under 37 CFR 1.53(b) and/or continuations/divisionals/CPAs under 37 CFR 1.53(d)) to maintain pendency hereof or of any such related application.

SUBMITTED BY: Sidley Austin LLP

Typed Name Gary L. Veron

Reg. No. 39,057

Signature

Gary Veron

Date

11/16/06



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Dan L. Eaton et al.	Group Art Unit: 1646
Serial No.: 10/015,967	Examiner: Dong Jiang
Filed: December 7, 2001	Attorney Docket No: 22338-501 (P1447R1)
Confirmation No.: 9428	
Title: Interleukin-8 Homologous Polypeptides and Therapeutic Uses Thereof	

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL AMENDMENT

Sir:

In response to the telephone interview of November 2, 2006, please amend the above-identified application as follows:

Amendments to the claims are reflected in the listing of claims that begins on page 2 of this paper.

Remarks begin on page 4 of this paper.

11/17/2006 SZEWDIE1 00000115 181260 10015967
01 FC:1201 200.00 DA